Search
isavuconazonium sulfate (Cresemba)
Indications:
- invasive aspergillosis
- invasive mucormycosis
Dosage:
- oral or intravenous administration
Adverse effects:
- nausea, vomiting
- constipation, diarrhea
- headache
- hepatotoxicity, abnormal liver function tests
- hypokalemia
- dyspnea
- cough
- peripheral edema
- infusion reactions
- severe allergic reactions
- Stevens-Johnson syndrome, toxic epidermal necrolysis or other severe skin reaction
Mechanism of action:
- azole that targets fungal cell wall
General
antifungal agent
pyrrole
aromatic compound
nitrile
ester
carbamate
Database Correlations
PUBCHEM cid=72196309
References
- FDA News Release. March 6, 2015.
FDA approves new antifungal drug Cresemba
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437106.htm